This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Pharmacological therapies mainly address symptoms and unfortunately a significant number of patients do not respond adequately, progressing to congestive heart failure and eventually needing a heart transplant. Frontiers in Pharmacology. Cardiovascular diseases are the leading cause of death globally with over 18.5 2019;33(1):209–22.
Patent Protection of Pharmacologically Active Metabolites: Theoretical and Technological Analysis on the Jurisprudence of Four Regions. 23 April 2013. Cited 25 September 2022]. Li-dar Wang R, Huang P-C. Santa Clara High Technology Law Journal. 29(3), article 2. Cited 25 September 2022].
While for other patients the possible adverse side effects from medication may prevent them from finding pharmacological therapies effective. She started working on this technology around 2013 after realizing the dire need for an alternative solution for mental disorders, and through realization that science can provide more answers.
She holds a MSc in Pharmacology. Marechal-Jamil has led European and International advocacy efforts across a wide range of topics: market access and health policies, and regulatory and scientific frameworks. References 1. Key Figures on Biosimilar medicines (2024). Internet] Biosimilar Medicines Group, Medicines for Europe.
Since the publication of the fifth Diagnostic and Statistical Manual of Mental Disorders in 2013, both conditions are grouped under the term FSIAD, which includes reduced arousal and interest. One Phase II trial was completed back in 2013, as per ClinicalTrials.gov.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content